APA (7th ed.) Citation

Wang, S., Wu, W., Shi, Z., Bin, M., Zhang, F., Cai, L., . . . Li, Z. (2025). SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Elsevier.

Chicago Style (17th ed.) Citation

Wang, Shanshan, Weicheng Wu, Zhen Shi, Mei Bin, Fengwei Zhang, Long Cai, Kaiqing Lin, and Zhihui Li. SMYD2 Epigenetically Activates BMP4/SMAD1/5/8/ID3 Axis to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. Elsevier, 2025.

MLA (9th ed.) Citation

Wang, Shanshan, et al. SMYD2 Epigenetically Activates BMP4/SMAD1/5/8/ID3 Axis to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. Elsevier, 2025.